Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How drug information fine print fails to communicate

Steve Woodruff
Meds
June 6, 2010
Share
Tweet
Share

As someone deeply immersed in pharma communications, and especially the newer realm of social networking, I’ve been closely following the ongoing process of the industry/FDA dance, trying to figure out how social media/web 2.0 approaches “fit” with pharmaceutical manufacturers and their various audiences.

And I keep wondering if we’re going about the whole thing the wrong way.

Think about the fine print PI (Product Information) you see in a magazine, accompanying a prescription drug ad. How many people do you think really read that? And, of that miniscule number, how many actually understand it?

This is not “communication.” It is “exposure of comprehensive required information.”

Now stop and think. If the joint goal of patients, doctors, regulators, and manufacturers is the right treatment given to the right patient at the right time for the right reason, then what we need is more than mere CYA disclosure. We need communication, designed properly for each audience, and digestible in ways that reflect how we genuinely communicate.

I’m in the process of selling and buying a house. And, roughly, there’s a 3-fold communication/thought process:

    1. Basic, initial go-or-no-go information that helps me figure out whether something might be for me (e.g., a 2-bedroom split-level with a flooding basement on a 0.2 acre lot near a highway is not of interest).
    2. A deeper layer of information that will let me whittle down further what matters, based on key points (e.g., a house visit with the realtor to really explore the place after all basic stuff has narrowed things down).
    3. All the inspection and contractual details that must be waded through (comprehensive disclosure) once we have a pretty good idea of direction (e.g., call the lawyers and examine the paperwork).

We don’t start with #3. But much of what passes for pharma communications is so hog-tied by regulatory pressure on the comprehensive disclosure front, that the cart is effectively placed before the horse — if the horse is even allowed to show up. Effective communication is severely hampered.

If we’ve done full disclosure, such that the FDA isn’t dropping big fines, yet we’re really not communicating effectively with about the right treatment for the right patient at the right time for the right reason, then I have to conclude that we’ve all failed. And that’s what I fear will happen with the proposed FDA guidance on social media in pharma – we’ll all be so tied up with the disclosure minefield that no one is paying attention to the real point – what does it mean to effectively communicate on every level about prescription drugs and health?

There are basic principles of instructional design and “layered” multi-channel communication that seem to me far more vital than an endless “cover your backside” fear-based pursuit of comprehensive disclosure. I’d far rather see time and creativity invested in designing a prescription drug product information portal with layers of information (digestible for all audiences), multimedia education, and controlled interactivity than figuring out how we’re going to stuff a full PI into a coffee mug, a magazine insert, a TV ad, or a tweet. Can’t we take advantage of all this linked and multi-channel approaches to communicate more effectively and completely, rather than less so?

Social media provides wonderful new ways to establish information-sharing and build bridges with stakeholders across the entire healthcare chain, from drug manufacturers all the way through to patients. But if we look at it through all the old lenses, I suspect we’ll end up with the same old communication constipation that we have now. That would be a shame.

Steve Woodruff is Founder and President of Impactiviti.

Submit a guest post and be heard.

Prev

Top 10 medical blog posts, May 2010

June 6, 2010 Kevin 2
…
Next

The New York Times changes the Dartmouth Atlas narrative

June 7, 2010 Kevin 7
…

ADVERTISEMENT

Tagged as: Medications

Post navigation

< Previous Post
Top 10 medical blog posts, May 2010
Next Post >
The New York Times changes the Dartmouth Atlas narrative

ADVERTISEMENT

More by Steve Woodruff

  • a desk with keyboard and ipad with the kevinmd logo

    Educated online by people with diabetes

    Steve Woodruff
  • a desk with keyboard and ipad with the kevinmd logo

    How business will affect pharmaceutical reps

    Steve Woodruff
  • a desk with keyboard and ipad with the kevinmd logo

    Why the female Viagra quest is fundamentally misguided

    Steve Woodruff

More in Meds

  • Tofacitinib: a lesson in heart-immune health

    Larry Kaskel, MD
  • The case for regulating, not banning, kratom

    Heidi Sykora, DNP, RN
  • How India-Pakistan tensions could break America’s generic drug pipeline

    Adwait Chafale
  • The unfair war on buprenorphine

    Brian Lynch, MD
  • Drug giants face suit over hidden cancer risks

    Martha Rosenberg
  • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

    Adwait Chafale
  • Most Popular

  • Past Week

    • A doctor’s letter from a federal prison

      L. Joseph Parker, MD | Physician
    • When language barriers become a medical emergency

      Monzur Morshed, MD and Kaysan Morshed | Physician
    • A surgeon’s view on RVUs and moral injury

      Rene Loyola, MD | Physician
    • Why doctors are losing the health care culture war

      Rusha Modi, MD, MPH | Policy
    • The hypocrisy of insurance referral mandates

      Ryan Nadelson, MD | Physician
    • A cancer doctor’s warning about the future of medicine

      Banu Symington, MD | Physician
  • Past 6 Months

    • Rethinking the JUPITER trial and statin safety

      Larry Kaskel, MD | Conditions
    • The ignored clinical trials on statins and mortality

      Larry Kaskel, MD | Conditions
    • How one physician redesigned her practice to find joy in primary care again [PODCAST]

      The Podcast by KevinMD | Podcast
    • I passed my medical boards at 63. And no, I was not having a midlife crisis.

      Rajeev Khanna, MD | Physician
    • Why doctors must fight for a just health care system

      Alankrita Olson, MD, MPH & Ashley Duhon, MD & Toby Terwilliger, MD | Policy
    • The silent disease causing 400 amputations daily

      Xzabia Caliste, MD | Conditions
  • Recent Posts

    • Love and loss in the oncology ward

      Dr. Damane Zehra | Physician
    • The weight of genetic testing in a family

      Rebecca Thompson, MD | Physician
    • A surgeon’s view on RVUs and moral injury

      Rene Loyola, MD | Physician
    • Meeting transgender patients with compassion and equity in health care [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why your health is a portfolio to manage

      Larry Kaskel, MD | Conditions
    • Reclaiming moral ambition in health care

      Mick Connors, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 3 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • A doctor’s letter from a federal prison

      L. Joseph Parker, MD | Physician
    • When language barriers become a medical emergency

      Monzur Morshed, MD and Kaysan Morshed | Physician
    • A surgeon’s view on RVUs and moral injury

      Rene Loyola, MD | Physician
    • Why doctors are losing the health care culture war

      Rusha Modi, MD, MPH | Policy
    • The hypocrisy of insurance referral mandates

      Ryan Nadelson, MD | Physician
    • A cancer doctor’s warning about the future of medicine

      Banu Symington, MD | Physician
  • Past 6 Months

    • Rethinking the JUPITER trial and statin safety

      Larry Kaskel, MD | Conditions
    • The ignored clinical trials on statins and mortality

      Larry Kaskel, MD | Conditions
    • How one physician redesigned her practice to find joy in primary care again [PODCAST]

      The Podcast by KevinMD | Podcast
    • I passed my medical boards at 63. And no, I was not having a midlife crisis.

      Rajeev Khanna, MD | Physician
    • Why doctors must fight for a just health care system

      Alankrita Olson, MD, MPH & Ashley Duhon, MD & Toby Terwilliger, MD | Policy
    • The silent disease causing 400 amputations daily

      Xzabia Caliste, MD | Conditions
  • Recent Posts

    • Love and loss in the oncology ward

      Dr. Damane Zehra | Physician
    • The weight of genetic testing in a family

      Rebecca Thompson, MD | Physician
    • A surgeon’s view on RVUs and moral injury

      Rene Loyola, MD | Physician
    • Meeting transgender patients with compassion and equity in health care [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why your health is a portfolio to manage

      Larry Kaskel, MD | Conditions
    • Reclaiming moral ambition in health care

      Mick Connors, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How drug information fine print fails to communicate
3 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...